Aibotics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.5M
- Price
- $0.0029
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.72%
- Volume
- 45.7M
About
Aibotics Inc., together with its subsidiaries, engages in the study of psychedelics for the treatment of mental health issues in the United States. It provides psychedelic methodologies for the treatment of palliative care, depression, and anxiety. The company was formerly known as Mycotopia Therapies, Inc. and changed its name to Aibotics Inc. in February 2025 Aibotics Inc. is based in Miami, Florida.
Quick stats
Shares outstanding850.2M
Computed float735.1M
Float / shares86.5%
Cash runway (months)11.6
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001763329
Websitehttps://aibotics.ai
AI Summary
AI-generated1/4
minorneutralm and a
AIBotics and Empulser Position ‘Power. Persistence. Autonomy.’ Strategy as Pentagon Accelerates Autonomous Warfare Capabilities
AIBotics tied its pending acquisition of Empulser Enterprises, a wireless-power and autonomous-systems defense-technology company, to the Pentagon's newly announced Autonomous Warfare Command and Project Agincourt.
The release is largely strategic positioning: Empulser's products remain in development, with testing, certification, customer adoption and commercialization all subject to engineering, financing and execution.
Forward-looking disclosures reference potential dilution from Series C Preferred Stock conversion, earn-out milestones, discretionary pre-closing loans, and a proposed management transition to Patrick Tsang as CEO, none of which is yet assured.
Red flags
- acquisition is pending and may not close; conditions include audited financials, filing status and due-diligence/termination rights
- potential dilution from conversion of Series C Preferred Stock
- earn-out consideration subject to milestone achievement and setoff/cancellation
- proposed CEO appointment of Patrick Tsang is contingent on conditions
- Empulser products are pre-commercialization with financing and execution risk
- promotional tone riding DoD policy headlines with no disclosed revenue, customers, or contract figures